Skip to content

Newsroom

type
year
reltype
Illustration image.png

Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline

10/28/2026 Stock exchange release
Illustration image.png

Changes in Orion Group’s Executive Team as of 1 January 2027

10/26/2026 Stock exchange release
Illustration image.png

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

10/24/2026 Press release
Illustration image.png

Inside information: Orion upgrades full-year outlook for 2026

10/20/2026 Stock exchange release
Illustration image.png

Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026

10/14/2026 Press release
Illustration image.png

125,000 Orion Corporation A shares converted into B shares

10/7/2026 Stock exchange release
Illustration image.png

Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market

10/6/2026 Press release
Illustration image.png

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing

10/5/2026 Press release
Illustration image.png

Orion Corporation completed share acquisitions

9/30/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 40, 2026

9/30/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 39, 2026

9/25/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 38, 2026

9/18/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 37, 2026

9/11/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 36, 2026

9/4/2026 Stock exchange release
Illustration image.png

102,000 Orion Corporation A shares converted into B shares

9/4/2026 Stock exchange release
Illustration image.png

Orion Corporation to commence acquisition of own shares for its share-based incentive plans

8/27/2026 Stock exchange release
Illustration image.png

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

8/10/2026 Stock exchange release
Illustration image.png

Orion Group Half-Year Financial Report January–June 2026

7/17/2026 Stock exchange release